Imagine a life-threatening storm raging through the body, crippling vital organs and defying doctors at every turn— that's sepsis, and it's claiming lives by the hour. But what if a single, overlooked molecule held the key to protecting the kidneys from its devastating grip? Dive into this groundbreaking study, and you'll discover how an unassuming long non-coding RNA named PCED1B-AS1 might just be the unsung hero in battling sepsis-induced acute kidney injury (AKI). It's a tale of scientific intrigue that could rewrite medical playbooks, but here's where it gets controversial— are we ready to embrace RNA therapies when traditional treatments fall short? Let's unpack it all, step by step, and see if this sparks your thoughts on the future of critical care.
Introduction
Sepsis stands as one of the most perilous conditions a person can face, marked by widespread organ failure triggered by the body's chaotic overreaction to an infection. It's a grim reality that leads to shockingly high death rates, and for many patients in intensive care, it often complicates matters with acute kidney injury (AKI). AKI in sepsis isn't just a side effect— it's a multi-faceted disaster involving altered blood flow to the kidneys, damaged endothelial cells, and an overzealous inflammatory storm. The prognosis is dire; studies show sepsis patients with AKI are three to five times more likely to succumb compared to those without kidney issues. Tragically, by the time symptoms become obvious, treatment often arrives too late. Early detection could make all the difference, allowing for timely interventions to halt progression.
And this is the part most people miss— mounting evidence suggests that long non-coding RNAs (lncRNAs), which don't code for proteins themselves, play pivotal roles in influencing how proteins are made and thus shape disease outcomes. Researchers are increasingly fascinated by how lncRNAs can be dysregulated in various illnesses, especially those like sepsis-related AKI. For instance, PCED1B-AS1 has been linked to cancer progression in conditions such as osteosarcoma, gastric cancer, and colorectal cancer. It also appears relevant in pain from pulpitis and helps regulate blood vessel cells in diabetic retinopathy. Intriguingly, a study by Zheng Liming and colleagues identified PCED1B-AS1 as downregulated in sepsis patients, hinting at its potential role. Yet, questions linger: Does this RNA show abnormal patterns specifically in sepsis-induced AKI, and what's the underlying mechanism?
Functionally, lncRNAs often act as sponges for microRNAs (miRNAs), softening their ability to silence target genes. miR-361-3p, for example, is overactive in diseases like Alzheimer's, acute myeloid leukemia, and various cancers, and it worsens heart damage in sepsis. This leads us to speculate that miR-361-3p is deeply involved in AKI tied to sepsis.
Enter the Suppressor of Cytokine Signaling (SOCS) family, key players that dial down inflammation by curbing cytokine signals. SOCS1, in particular, maintains immune balance by preventing runaway T-cell activation and has shown promise in reducing inflammation in kidney conditions like mesangial proliferative glomerulonephritis (MsPGN). It also acts as a guardian against excessive swelling in sepsis, reprogramming metabolism to shield organs. Bioinformatics hints at a connection between SOCS1 and miR-361-3p, suggesting miR-361-3p might control SOCS1 levels.
This research aims to explore PCED1B-AS1's expression in sepsis-induced AKI, using initial lab tests to uncover its molecular influences. We'll also investigate its role in the miR-361-3p/SOCS1 pathway and how it impacts AKI development.
Materials and Methods
Our study strictly follows the Helsinki Declaration, with full participant consent and approval from the Institutional Review Board at Affiliated Hospital of Youjiang Medical University for Nationalities. Sample size was calculated using GPower software, targeting a power of 0.8, effect size of 0.25, and alpha of 0.05, yielding at least 153 participants. We recruited 110 sepsis patients with AKI and 110 without, plus 105 healthy controls from the ICU, all enrolled within 24 hours of symptom onset per the Third International Consensus Definitions for Sepsis and Septic Shock. AKI diagnosis used KDIGO guidelines, excluding those with chronic kidney issues, nephrotoxic drug use, or other conditions like infections or autoimmune diseases.
Blood samples were collected, allowed to clot for 30 minutes, and centrifuged at a specific speed for 10 minutes to isolate serum, stored at -80°C for analysis. A 28-day follow-up tracked mortality, with data analyzed via Kaplan-Meier and Cox regression.
For cell work, we cultured RAW264.7 mouse macrophages and HK-2 human kidney tubular cells in DMEM with 10% FBS, at 37°C in a CO2 incubator. Macrophages were polarized with 10μg/mL LPS for 24 hours, and their conditioned media (CM) treated HK-2 cells similarly.
Transfections used plasmids for PCED1B-AS1 overexpression (oe-PCED1B-AS1) or empty vectors (oe-NC), and miR-361-3p mimics or inhibitors (GenePharma), delivered via Lipofectamine 3000.
RNA extraction via Trizol, reverse transcription, and qPCR with SYBR Green quantified levels, normalized to GAPDH or U6. Relative expression used the 2−ΔΔCt method.
Cell viability was measured with CCK-8 reagent at 450 nm after 24 hours. Apoptosis used Annexin V-FITC and propidium iodide, read by flow cytometry. Cytokine levels (TNF-α, IL-6, IL-1β, IL-10, TGF-β) were assessed by ELISA in pg/mL.
Proteins were extracted with RIPA buffer, quantified, separated by 10% SDS-PAGE, transferred to PVDF, blocked, and probed with antibodies, visualized by ECL and ImageJ.
Dual-luciferase assays used StarBase to predict miR-361-3p bindings to PCED1B-AS1 and SOCS1 3'UTR, cloned into pGL3 vectors (wt and mut), co-transfected with mimics/inhibitors, and luciferase measured after 48 hours.
For the animal model, we induced sepsis in 220–250g male Sprague-Dawley rats via cecal ligation and puncture (CLP), with sham controls. Kidneys were harvested 24 hours post-anesthesia.
Statistics: Means ± SD, analyzed by GraphPad Prism 9.0 and SPSS 26.0. ROC curves for diagnostics, Kaplan-Meier and Cox for survival. t-tests for two groups, ANOVA for multiple. Experiments in triplicate.
Results
Patient baselines showed no differences in age or gender across groups (P>0.05). Compared to healthy controls, non-AKI sepsis patients had higher CRP and NGAL, lower eGFR (P<0.001). AKI patients showed even greater elevations in CRP, Scr, BUN, NGAL, and lower eGFR, plus higher SOFA and APACHE II scores than non-AKI (P<0.001) (Table 1).
PCED1B-AS1 levels dropped significantly in non-AKI sepsis vs. controls (95% CI=0.233 to 0.325, P<0.001), and further in AKI (95% CI=0.133 to 0.224, P<0.001) (Figure 1A). It distinguished non-AKI from healthy (AUC=0.886, sensitivity=88.2%, specificity=81.9%, 95% CI=0.840 to 0.932) and AKI from non-AKI (AUC=0.888, sensitivity=86.4%, specificity=80.9%, 95% CI=0.843 to 0.932) (Figure 1B-C).
Dividing non-AKI patients by PCED1B-AS1 levels revealed lower 28-day survival in low-expression groups (Log Rank P=0.041) (Figure 2A). In AKI, low levels correlated with worse Scr, eGFR, NGAL, SOFA, APACHE II, but not CRP (Table 2). Survival was poorer in low-expression AKI (Log Rank P=0.017), and it was an independent prognostic factor (HR=0.354, 95% CI=0.147 to 0.856, P=0.021) (Figure 2C).
miR-361-3p rose in non-AKI sepsis vs. controls (95% CI=−0.489 to −0.357, P<0.001), and further in AKI (95% CI=−0.477 to −0.347, P<0.001) (Figure 3A). It negatively correlated with PCED1B-AS1 in AKI (r=−0.783, 95% CI=−0.846 to −0.698, P<0.001) (Figure 3B). Dual-luciferase showed miR-361-3p suppressed wt-PCED1B-AS1 activity (95% CI=0.209 to 0.751, P<0.001), while inhibition boosted it (95% CI=−0.814 to −0.272, P<0.001) (Figure 3C).
In LPS-treated macrophages, PCED1B-AS1 fell (95% CI=0.303 to 0.664, P<0.001), miR-361-3p rose (95% CI=−0.826 to −0.287, P<0.001), but overexpression increased PCED1B-AS1 (95% CI=−0.474 to −0.113, P<0.01) and decreased miR-361-3p (95% CI=0.194 to 0.733, P<0.001); mimic reversed this (95% CI=−0.589 to −0.051, P<0.05) (Figure 4A-B). LPS boosted M1 markers (iNOS, CD80) (P<0.001) and reduced M2 (Arg1, CD206) (P<0.001), but PCED1B-AS1 overexpression flipped this, lowering M1 and raising M2; mimic countered it (Figure 4C-D).
In CM-treated HK-2 cells, PCED1B-AS1 dropped (95% CI=0.183 to 0.657, P<0.01), miR-361-3p rose (95% CI=−1.052 to −0.588, P<0.001), overexpression restored PCED1B-AS1 (95% CI=−0.621 to −0.146, P<0.01) and lowered miR-361-3p (95% CI=0.368 to 0.832, P<0.001); mimic opposed (95% CI=−0.586 to −0.121, P<0.01) (Figure 5A-B). CM reduced viability (95% CI=0.517 to 0.822, P<0.001), increased apoptosis (95% CI=−15.070 to −8.242, P<0.001), and altered cytokines (TNF-α, IL-1β, IL-6 up; IL-10, TGF-β down, P<0.001). Overexpression improved viability (95% CI=−0.566 to −0.261, P<0.001), reduced apoptosis (95% CI=5.582 to 12.41, P<0.001), and balanced cytokines; mimic reversed (Figure 5C-F).
SOCS1 decreased in non-AKI (95% CI=0.318 to 0.389, P<0.001) and AKI (95% CI=0.221 to 0.291, P<0.001) (Figure 6A), negatively correlating with miR-361-3p (r=−0.708, P<0.001) (Figure 6B). Dual-luciferase confirmed binding: mimic suppressed wt-SOCS1 (95% CI=0.207 to 0.613, P<0.001), inhibitor enhanced (95% CI=−0.589 to −0.184, P<0.001) (Figure 6C). In LPS macrophages and CM HK-2, SOCS1 fell (P<0.001), but overexpression raised it (P<0.001); mimic lowered (Figure 6D-G).
si-SOCS1 opposed PCED1B-AS1's effects on SOCS1 mRNA/protein in macrophages (Figure 7A-B), M1/M2 markers (Figure 7C-D), and in HK-2, on SOCS1, proliferation (95% CI=0.240 to 0.413, P<0.001), apoptosis (95% CI=−11.01 to −3.966, P<0.001), and cytokines (Figure 7E-J).
In septic rat kidneys, PCED1B-AS1 decreased (95% CI=−0.602 to −0.278, P<0.001), miR-361-3p increased (95% CI=0.430 to 0.806, P<0.001), SOCS1 decreased (95% CI=−0.627 to −0.309, P<0.001) (Supplementary Figure 1).
Discussion
AKI in sepsis is a critical illness with rapid onset and severe inflammation, leading to poor outcomes. Here, PCED1B-AS1 was downregulated in sepsis-AKI, potentially as a diagnostic and prognostic marker. Lab experiments suggest it curbs AKI by shifting macrophages from inflammatory M1 to healing M2 types. This lays groundwork for PCED1B-AS1 in sepsis-AKI treatment.
Other lncRNAs like NEAT1 and PMS2L2 are abnormal in sepsis-AKI, offering protective roles. NEAT1 has diagnostic value (AUC=0.851), linking to severity and prognosis (AUC=0.730). Our study found PCED1B-AS1's AUC of 0.886 for sepsis vs. healthy, matching prior sepsis findings, and newly distinguishes AKI from non-AKI. Low levels tied to worse markers (Scr, eGFR, NGAL) and higher death risk, indicating its role.
Cox analysis identified PCED1B-AS1 as independent for prognosis, alongside eGFR. But eGFR's dynamic nature in AKI raises questions— is it the best confounder? Future work could combine PCED1B-AS1 with markers for better prediction. But here's where it gets controversial: Could PCED1B-AS1 outperform eGFR in real-world settings, or are we overlooking simpler blood tests?
Sepsis-AKI links to immunity, especially M2 macrophages, which aid tubular regeneration and reduce inflammation. They counteract M1 harm. Our findings show PCED1B-AS1 promotes M2 polarization, cutting HK-2 apoptosis and swelling, like NEAT1 or GAS6-AS2. And this is the part most people miss— by boosting cell growth and taming inflammation, PCED1B-AS1 mirrors therapies targeting similar pathways.
PCED1B-AS1 sponges miR-361-3p, as in cancers; we saw mimics reversing its protective effects. SOCS1, targeted by miR-361-3p, fights sepsis inflammation and M1 polarization. Thus, PCED1B-AS1 likely shields via miR-361-3p/SOCS1, shifting macrophages to alleviate AKI.
Limitations include no comparison with NEAT1/GAS6-AS2 in the same cohort— future studies should to assess PCED1B-AS1's strengths. Animal models confirmed expression changes but lack deep in vivo mechanism tests; overexpressing PCED1B-AS1 in mice could validate. We measured mRNA markers but could add flow cytometry for precision. Time-course data pre-AKI is missing; serial sampling in models needed. Cell sources weren't pinpointed; sorting subpopulations could help. Other pathways await exploration.
Conclusion
PCED1B-AS1 decreases in sepsis and sepsis-AKI, serving as a diagnostic/prognostic tool. Its upregulation via miR-361-3p/SOCS1 promotes M2 macrophage shift, reducing HK-2 apoptosis and inflammation.
Data Sharing Statement
All data from this study appear in the article; contact the corresponding author for more.
Funding
Supported by Guangxi Health Commission (S2022135), Baise Scientific Research & Technological Development Plan (20224107), and Affiliated Hospital of Youjiang Medical University for Nationalities High-Level Talent Projects (R20212608).
Disclosure
No conflicts declared.
References
Wang Q-L, Xing W, Yu C, Gao M, Deng L-T. ROCK1 regulates sepsis-induced acute kidney injury via TLR2-mediated endoplasmic reticulum stress/pyroptosis axis. Molecular Immunol. 2021;138:99–109. doi:10.1016/j.molimm.2021.07.022
Huang P, Meng L, Pang J, Huang H, Ma J, He L, Lin, X. miR-208a-3p regulated by circUQCRC2 suppresses ischemia/reperfusion-induced acute kidney injury by inhibiting CELF2-mediated tubular epithelial cell apoptosis, inflammation and ferroptosis. Shock. 2024;61(6):942–950. doi:10.1097/SHK.0000000000002339
Jiang L, Ni J, Shen G, et al. Upregulation of endothelial cell-derived exosomal microRNA-125b-5p protects from sepsis-induced acute lung injury by inhibiting topoisomerase II alpha. Inflamm Res. 2021;70(2):205–216.
Liu Z, Yang D, Gao J, et al. Discovery and validation of miR-452 as an effective biomarker for acute kidney injury in sepsis. Theranostics. 2020;10(26):11963–11975.
Koyner JL. Sepsis and Kidney Injury. Contribut Nephrol. 2021;199:56–70.
Esteller M. Non-coding RNAs in human disease. Nat Rev Gene. 2011;12(12):861–874.
Brandenburger T, Salgado Somoza A, Devaux Y, Lorenzen JM. Noncoding RNAs in acute kidney injury. Kidney Inter. 2018;94(5):870–881.
Zhao H, Chen B, Li Z, Wang B, Li L. Long noncoding RNA DANCR suppressed lipopolysaccharide-induced septic acute kidney injury by regulating miR-214 in HK-2 cells. Med Sci Monitor. 2020;26:e921822.
Shi C, Zhao Y, Li Q, Li J. lncRNA SNHG14 plays a role in sepsis-induced acute kidney injury by regulating miR-93. Mediators Inflamm. 2021;2021:5318369.
Wang B, Yao L, Dong Y, Liu J, Wu J. LncRNA PCED1B-AS1 knockdown inhibits osteosarcoma via methylation-mediated miR-10a downregulation. J Orthopaedic Surg Res. 2022;17(1):464. doi:10.1186/s13018-022-03284-1
Cao J, Yang Y, Duan B, et al. LncRNA PCED1B-AS1 mediates miR-3681-3p/MAP2K7 axis to promote metastasis, invasion and EMT in gastric cancer. Biology Direct. 2024;19(1):34. doi:10.1186/s13062-024-00468-z
Liu J, Qian J, Mo Q, Tang L, Xu Q. Long non-coding RNA PCED1B-AS1 promotes the proliferation of colorectal adenocarcinoma through regulating the miR-633/HOXA9 axis. Bioengineered. 2022;13(3):5407–5420. doi:10.1080/21655979.2022.2037225
Tan Y, He Y, Xu Y, et al. Identification of pain-related long non-coding RNAs for pulpitis prediction. Clin Oral Invest. 2025;29(1):75. doi:10.1007/s00784-025-06164-0
Wang X, Chen W, Lao W, Chen Y. Upregulation of PCED1B-AS1 in proliferative diabetic retinopathy and its involvement in retinal vascular endothelial cell proliferation. BMC Ophthalmol. 2022;22(1):450. doi:10.1186/s12886-022-02683-6
Zheng L-M, Ye J-Q, Li H-F, Liu Q. Construction of a potentially functional lncRNA-miRNA-mRNA network in sepsis by bioinformatics analysis. Front Gene. 2022;13:1031589. doi:10.3389/fgene.2022.1031589
Paraskevopoulou MD, Hatzigeorgiou AG. Analyzing MiRNA-LncRNA Interactions. Meth Molecular Biolog. 2016;1402:271–286.
Ji Y, Wang D, Zhang B, Lu H. MiR-361-3p inhibits β-amyloid accumulation and attenuates cognitive deficits through targeting BACE1 in Alzheimer’s disease. J Integrat Neurosci. 2019;18(3):285–291. doi:10.31083/j.jin.2019.03.1136
Liu S, Xu H, Li Z. Linoleic acid derivatives target miR-361-3p/BTG2 to confer anticancer effects in acute myeloid leukemia. J Biochem Mole Toxicol. 2023;37(11):e23481. doi:10.1002/jbt.23481
Liu J, Zhu J, Xiao Z, Wang X, Luo J. BBOX1-AS1 contributes to colorectal cancer progression by sponging hsa- miR-361-3p and targeting SH2B1. FEBS Open Bio. 2022;12(5):983–992. doi:10.1002/2211-5463.12802
Zhou Y, Zhang Q, Liao B, Qiu X, Hu S, Xu Q. circ_0006089 promotes gastric cancer growth, metastasis, glycolysis, and angiogenesis by regulating miR-361-3p/TGFB1. Cancer Sci. 2022;113(6):2044–2055. doi:10.1111/cas.15351
Geng H, Qi L, You L, Feng W, Yang X, Lei M. miR-361-3p overexpression promotes apoptosis and inflammation by regulating the USP49/IκBα/NF-κB pathway to aggravate sepsis-induced myocardial injury. Toxicol Res. 2024;13(6):tfae190. doi:10.1093/toxres/tfae190
Bidgood GM, Keating N, Doggett K, Nicholson SE. SOCS1 is a critical checkpoint in immune homeostasis, inflammation and tumor immunity. Front Immunol. 2024;15:1419951. doi:10.3389/fimmu.2024.1419951
Ilangumaran S, Bobbala D, Ramanathan S. SOCS1: regulator of T cells in autoimmunity and cancer. Curr Topics Microbiol Immunol. 2017;410:159–189.
Zhao Y, Peng F, He J, et al. SOCS1 peptidomimetic alleviates glomerular inflammation in MsPGN by inhibiting macrophage M1 polarization. Inflammation. 2023;46(6):2402–2414.
Davey GM, Heath WR, Starr R. SOCS1: a potent and multifaceted regulator of cytokines and cell-mediated inflammation. Tissue Antigens. 2006;67(1):1–9.
Piñeros Alvarez AR, Glosson-Byers N, Brandt S, et al. SOCS1 is a negative regulator of metabolic reprogramming during sepsis. JCI Insight. 2017;2(13).
Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315(8):801–810.
Ostermann M, Bellomo R, Burdmann EA, et al. Controversies in acute kidney injury: conclusions from a kidney disease: improving global outcomes (KDIGO) conference. Kidney Inter. 2020;98(2):294–309.
Poston JT, Koyner JL. Sepsis associated acute kidney injury. BMJ. 2019;364:k4891.
Zhou Y, Wang Y, Li Q, et al. Downregulation of lncRNA NEAT1 alleviates sepsis-induced acute kidney injury. Central Euro J Immunol. 2022;47(1):8–19.
Zhang F, Luo X, Wang Y, Ma L, Sun D. LncRNA pms2l2 is downregulated in sepsis-induced acute kidney injury and inhibits LPS-induced apoptosis of podocytes. Kidney Blood Pressure Res. 2023;48(1):515–521.
Huang Q, Huang C, Luo Y, He F, Zhang R. Circulating lncRNA NEAT1 correlates with increased risk, elevated severity and unfavorable prognosis in sepsis patients. Ame J Emerg Med. 2018;36(9):1659–1663.
Ge J, Zhang X, Liu Y, Liu H, Liu X. miR-874-3p is identified as a biomarker for acute kidney injury and mediates disease development via targeting MSRB3. Nephron. 2024;148(6):426–436.
Pu M, Zhao H, Xu S, Gu X, Feng Q, Huang P. Urine miR-340-5p predicts the adverse prognosis of sepsis-associated acute kidney injury and regulates renal tubular epithelial cell injury by targeting KDM4C. Nephron. 2025;149(4):197–206.
Wang X, Chen J, Xu J, Xie J, Harris DCH, Zheng G. The role of macrophages in kidney fibrosis. Front Physiolog. 2021;12:705838.
Wen Y, Crowley SD. The varying roles of macrophages in kidney injury and repair. Curr Opinion Nephrolog Hyperten. 2020;29(3):286–292.
Chen T, Cao Q, Wang Y, Harris DCH. M2 macrophages in kidney disease: biology, therapies, and perspectives. Kidney International. 2019;95(4):760–773.
Wang W, Guo ZH. Downregulation of lncRNA NEAT1 ameliorates LPS-induced inflammatory responses by promoting macrophage M2 polarization via miR-125a-5p/TRAF6/TAK1 axis. Inflammation. 2020;43(4):1548–1560.
Cui H, Ren G, Hu X, et al. Suppression of lncRNA GAS6-AS2 alleviates sepsis-related acute kidney injury through regulating the miR-136-5p/OXSR1 axis in vitro and in vivo. Renal Failure. 2022;44(1):1070–1082.
Ding H, He J, Xiao W, Ren Z, Gao W. LncRNA PCED1B-AS1 upregulation in hepatocellular carcinoma and regulation of the miR-10a/BCL6 axis to promote cell proliferation. Crit Rev Eukaryotic Gene Express. 2022;32(6):11–20.
Zhang Y, Ma H, Chen C. Long non‑coding RNA PCED1B‑AS1 promotes pancreatic ductal adenocarcinoma progression by regulating the miR‑411‑3p/HIF‑1α axis. Oncol Rep. 2021;46(1).
Jiao Y, Zhang T, Zhang C, et al. Exosomal miR-30d-5p of neutrophils induces M1 macrophage polarization and primes macrophage pyroptosis in sepsis-related acute lung injury. Critical Care. 2021;25(1):356.
Huang S, Qian K, Zhu Y, Huang Z, Luo Q, Qing C. Diagnostic value of the lncRNA NEAT1 in peripheral blood mononuclear cells of patients with sepsis. Disease Markers. 2017;2017:7962836.
What do you think— is PCED1B-AS1 the breakthrough we've been waiting for in sepsis treatment, or could it lead to unintended side effects? Share your opinions in the comments; let's debate the pros and cons!
